866-997-4948(US-Canada Toll Free)

EpiCast Report: Chronic Lymphocytic Leukemia - Epidemiology Forecast to 2025

Published By :

GlobalData

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 47 Pages

EpiCast Report: Chronic Lymphocytic Leukemia - Epidemiology Forecast to 2025

Summary

Chronic lymphocytic leukemia (CLL), also known as chronic lymphoid leukemia, is a type of cancer of the white blood cells (lymphocytes). CLL affects a particular lymphocyte, the B cell, which accumulates mainly in the bone marrow and blood, and normally fights infection. CLL is closely related to small lymphocytic lymphoma (SLL), a type of non-Hodgkin's lymphoma that presents primarily in the lymph nodes.

GlobalData epidemiologists utilized national databases and robust peer-reviewed journal articles to build the CLL diagnosed incident and five-year diagnosed prevalent cases forecast in the 7MM. The disease definition for CLL was consistent with the ICD-10 code C91.1. Whenever available, country-specific sources were utilized and in case of data scarcity, appropriate proxies were used to fill the data gaps.

In the 7MM, GlobalData epidemiologists forecast an increase in the diagnosed incident cases of CLL from 40,631 diagnosed incident cases in 2015 to 49,643 diagnosed incident cases in 2025, with an annual growth rate (AGR) of 2.22% during the forecast period. The US will have the highest number of diagnosed incident cases of CLL among the 7MM throughout the forecast period, while Spain will have the lowest.

Scope

- The Chronic lymphocytic leukemia (CLL) EpiCast Report provides an overview of the risk factors and global trends of CLLin the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- The report includes a 10-year epidemiological forecast for the diagnosed incident cases of CLL and five-year diagnosed prevalent cases of CLL. Incident cases are segmented by age, sex, Rai and Binet stage at diagnosis, symptom status (symptomatic vs. asymptomatic), and immunoglobulin heavy chain variable (IGHV) region gene mutation status (mutated vs. unmutated) for the 7MM. The diagnosed incident cases of CLL with the mutations 17p deletion, 11q deletion, and TP53 are also provided in the report.
- The CLL epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The CLL EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global CLL market.
- Quantify patient populations in the global CLL market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CLL therapeutics in each of the markets covered.
- Understand magnitude of CLL population by two staging systems.
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Executive Summary 5
2.1 Related Reports 8
2.2 Upcoming Reports 8
3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 10
3.3 Global and Historical Trends 11
3.4 Forecast Methodology 13
3.4.1 Sources 14
3.4.2 Forecast Assumptions and Methods 21
3.4.3 Diagnosed Incident Cases 22
3.4.4 Diagnosed Incident Cases by Stage at Diagnosis (Rai Staging) 24
3.4.5 Diagnosed Incident Cases by Stage at Diagnosis (Binet Staging) 24
3.4.6 Diagnosed Incident Cases by Disease Symptom Status 25
3.4.7 Mutations (17p deletion, 11q Deletion, and TP53) Among the Diagnosed Incident Cases of CLL 25
3.4.8 IGHV Mutation Among Diagnosed Incident Cases of CLL 27
3.4.9 Five-Year Diagnosed Prevalent Cases of CLL 28
3.5 Epidemiological Forecast for CLL (2015-2025) 29
3.5.1 Diagnosed Incident Cases of CLL 29
3.5.2 Age-Specific Diagnosed Incident Cases of CLL 30
3.5.3 Sex-Specific Diagnosed Incident Cases of CLL 31
3.5.4 Diagnosed Incident Cases of CLL by Stage at Diagnosis (Rai Staging) 32
3.5.5 Diagnosed Incident Cases of CLL by Stage at Diagnosis (Binet Staging) 33
3.5.6 Diagnosed Incident Cases of CLL by Disease Symptom Status 34
3.5.7 Diagnosed Incident Cases of CLL with 17p Deletion 35
3.5.8 Diagnosed Incident Cases of CLL with 11q Deletion 36
3.5.9 Diagnosed Incident Cases of CLL with TP53 Mutation 37
3.5.10 Diagnosed Incident Cases of CLL by IGHV Mutation Status 38
3.5.11 Five-Year Diagnosed Prevalent Cases of CLL 38
3.6 Discussion 39
3.6.1 Epidemiological Forecast Insight 39
3.6.2 Limitations of Analysis 40
3.6.3 Strengths of Analysis 40
4 Appendix 42
4.1 Bibliography 42
4.2 About the Authors 45
4.2.1 Epidemiologist 45
4.2.2 Reviewers 45
4.2.3 Global Director of Therapy Analysis and Epidemiology 46
4.2.4 Global Head and EVP of Healthcare Operations and Strategy 46
4.3 About GlobalData 47
4.4 Contact Us 47
4.5 Disclaimer 47

1.1 List of Tables
Table 1: CLL Clinical Stages 10
Table 2: Risk Factors and Comorbidities for CLL 11
Table 3: 7MM, Diagnosed Incident Cases of CLL, Both Sexes, Ages 18 Years, Selected Years 2015-2025. 29
Table 4: 7MM, Five-Year Diagnosed Prevalent Cases of CLL, Both Sexes, Ages 18 Years, Selected Years 2015-2025 39

1.2 List of Figures
Figure 1: 7MM, Diagnosed Incident Cases of CLL, Both Sexes, Ages 18 Years, 2015 and 2025 6
Figure 2: 7MM, Five-Year Diagnosed Prevalent Cases of CLL, Both Sexes, Ages 18 Years , 2015 and 2025 7
Figure 3: 7MM, CLL Age-Standardized Diagnosed Incidence (Cases per 100,000 Population), Men, Ages 18 Years, 2005 to 2025 12
Figure 4: 7MM, CLL Age-Standardized Diagnosed Incidence (Cases per 100,000 Population), Women, Ages 18 Years, 2005 to 2025 13
Figure 5: 7MM, Sources Used, Diagnosed Incident Cases of CLL 14
Figure 6: 7MM, Sources Used, Diagnosed Incident Cases of CLL by Stage at Diagnosis (Rai Staging) 15
Figure 7: 7MM, Sources Used, Diagnosed Incident Cases of CLL by Stage at Diagnosis (Binet Staging) 16
Figure 8: 7MM, Sources Used, 17p Deletion Among the Diagnosed Incident Cases of CLL 17
Figure 9: 7MM, Sources Used, 11q Deletion Among the Diagnosed Incident Cases of CLL 18
Figure 10: 7MM, Sources Used, TP53 Mutation Among the Diagnosed Incident Cases of CLL 19
Figure 11: 7MM, Sources Used, Diagnosed Incident Cases of CLL by IGHV Mutation Status 20
Figure 12: 7MM, Sources Used and Not Used, Five-Year Diagnosed Prevalent Cases of CLL 21
Figure 13: 7MM, Age-Specific Diagnosed Incident Cases of CLL, Both Sexes, Ages 18 Years, 2015 30
Figure 14: 7MM, Sex-Specific Diagnosed Incident Cases of CLL, Both Sexes, Ages 18 Years, 2015 31
Figure 15: 7MM, Diagnosed Incident Cases of CLL by Stage at Diagnosis (Rai Staging), Both Sexes, Ages 18 Years, 2015 32
Figure 16: 7MM, Diagnosed Incident Cases of CLL by Stage at Diagnosis (Binet Staging), Both Sexes, Ages 18 Years, 2015 33
Figure 17: 7MM, Diagnosed Incident Cases of CLL by Disease Symptom Status, Both Sexes, Ages 18 Years, 2015 34
Figure 18: 7MM, Diagnosed Incident Cases of CLL with 17p Deletion, Both Sexes, Ages 18 Years, 2015 35
Figure 19: 7MM, Diagnosed Incident Cases of CLL with 11q Deletion, Both Sexes, Ages 18 Years, 2015 36
Figure 20: 7MM, Diagnosed Incident Cases of CLL with TP53 Mutation, Both Sexes, Ages 18 Years, 2015 37
Figure 21: 7MM, Diagnosed Incident Cases of CLL by IGHV Mutational Status, Both Sexes, Ages 18 Years, 2015 38

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *